Insider trade

X4 Pharmaceuticals (XFOR): Director received 110K units

Kelly Gold, Director at X4 Pharmaceuticals, reported a grant / award of 110K units.

110K
Derivative units
Traded
Jul 1, 2026
Filed
Jul 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“At the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of shares available for issuance under the Plan by 1,500,000 shares.”
  2. May 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“At the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of shares available for issuance under the Plan by 1,500,000 shares.”
  3. May 12, 2026InsiderCFO sold ~$73K of XFOR shares in the open market
  4. Jun 30, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026. In connection with Ms. Gold’s appointment, the size of the Company’s board of directors (the “Board”) was increased from five to six directors.”
  5. Jun 30, 2026InsiderCFO sold ~$36K of XFOR shares in the open market

What came next

  1. Aug 12, 2026Insider · 2 peopleInsiders: 2 sales (~$320K)
  2. Oct 1, 2026InsiderCFO sold ~$34K of XFOR shares in the open market
  3. Oct 7, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 3 more items)
  4. Oct 7, 20265% stakeFMR LLC reported a passive stake (13G) of 4.6%
  5. Oct 16, 2026InsiderChair purchased ~$12K of XFOR shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for X4 Pharmaceuticals

For X4 Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XFOR page.

Other recent filings by Kelly Gold, Director

The full history of Kelly Gold, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which X4 Pharmaceuticals (XFOR) insider traded, and how much?

Kelly Gold, Director at X4 Pharmaceuticals, reported a grant / award of 110K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jul 1, 2026. Filed: Jul 2, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about X4 Pharmaceuticals recently?

For X4 Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the XFOR page.

Does this mean XFOR stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at X4 Pharmaceuticals

Everything OQRO holds on this company is on its XFOR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data